THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

January 26, 2022

Daily Change in COVID-19 Cases, US

January 22, 2020 – January 24, 2022

TOTAL Cases Reported Since 1/22/20

71,818,876

NEW Cases Reported to CDC on 1/24/22

1,140,580

Change in 7-Day Case Average

-6.2%

Current 7-Day Case Average (1/18/22 - 1/24/22)

692,359

Prior 7-Day Case Average (1/11/22 - 1/17/22)

737,733



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – January 23, 2022

Patients Currently Hospitalized with COVID on 1/23/22

134,359

New Admissions on 1/23/22

16,238

Peak in New Admissions (1/12/22)

23,045

Change in 7-Day Average of New Admissions

-8.2%

Current 7-Day Average of New Admissions (1/17/22 - 1/23/22)

19,754

Prior 7-Day Average of New Admissions (1/10/22 - 1/16/22)

21,509



Daily Change in COVID-19 Deaths, US

January 22, 2020 – January 24, 2022

TOTAL Deaths Reported Since 1/22/2020

866,968

NEW Deaths Reported to CDC on 1/24/22

2,643

Change in 7-Day Death Average

+20.9%

Current 7-Day Death Average (1/18/22 - 1/24/22)

2,166

Prior 7-Day Death Average (1/11/22 - 1/17/22)

1,791

Forecasted New Deaths in the week ending 02/12/22)

9,800 to 35,700



Cases, hospitalizations, and deaths during Omicron period compared with Delta period and Winter 2020–21



Source: CDC State Reported Data and Unified Hospital Dataset

The New England Journal of Medicine

Established in 1812 as THE NEW ENGLAND JOURNAL OF MEDICINE AND SURGERY

Published online December 15, 2021

Perspective

Universal Coronavirus Vaccines — An Urgent Need

David M. Morens, M.D., Jeffery K. Taubenberger, M.D., Ph.D., and Anthony S. Fauci, M.D.

- In the past 20 years, three coronaviruses have caused major disease outbreaks – **SARS, MERS, COVID-19**
- Since September 2020, five SARS-CoV-2 **Variants of Concern** have emerged – alpha, beta, gamma, delta, omicron
- Innovative approaches are needed to induce broad and durable protection against coronaviruses, known and unknown

Pan-Coronavirus Vaccines

Coronavirus Phylogenetic Tree



Source: SM Gygli, PhD, NIAID. Based on 440 bp nucleotide sequences of RNA-dependent RNA polymerase.

Pan-SARS-CoV-2 Vaccine

WHO Variants of Concern:

- Alpha
- Beta
- Gamma
- Delta
- Omicron



Pan-Sarbecovirus Vaccine



NIAID Research on Pan-Coronavirus Vaccines

- NIAID has invested/awarded >$3.5 billion overall on coronavirus research since the COVID-19 pandemic began
- Coronavirus vaccine research (total so far): $1.4 billion
  - Substantial investment in pan-coronavirus vaccine research in intramural and extramural programs
- Sept. 2021-Jan. 2022 awards: $42.8 million in funding over 3 years, to 4 academic institutions, for research to develop vaccines to protect against multiple types of coronaviruses and viral variants
- Additional awards anticipated in fiscal year 2022



Ongoing Projects: 5 Examples of Promising Pan-Coronavirus Vaccine Candidates

A Platform Incorporating Trimeric Antigens into Self-assembling Nanoparticles Reveals SARS-CoV-2-spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone

B Zhang, PD Kwong et al.

Mosaic Nanoparticles Elicit Cross-Reactive Immune Responses to Zoonotic Coronaviruses in Mice

AA Cohen, PJ Bjorkman et al.

A SARS-CoV-2 Ferritin Nanoparticle Vaccine Elicits Protective Immune Responses in Nonhuman Primates

MG Joyce, K Modjarrad et al.

Neutralizing Antibody Vaccine for Pandemic and Pre-Emergent Coronaviruses

KO Saunders, BF Haynes et al.

Elicitation of Broadly Protective Sarbecovirus Immunity by Receptor-Binding Domain Nanoparticle Vaccines

AC Walls, D Veesler et al.


Vaccine Construct
Vaccine Immunogen
Vaccine Platform

Example of a Pan-Coronavirus Vaccine Concept



Nanoparticle with different spike protein fragments

Vaccine

Diverse antibody response

Source: Bjorkman et al. 2021 *Science*

Example of a Universal Beta-Coronavirus Vaccine Concept



Inactivated, whole virus vaccine consisting of SARS-CoV-2 and several different coronaviruses delivered by intranasal mist

Broad protection against human and animal beta-coronaviruses

Source: Taubenberger, et al. 2022 Unpublished

Key Points

- Pan-coronavirus vaccine candidates will take time to develop

- Our current vaccine regimens provide strong protection against severe COVID-19 and death

- **Do not wait to receive your primary vaccine regimen or booster, if you are eligible**

THE WHITE HOUSE
WASHINGTON

WH.GOV